NewAmsterdam Pharma Co NV
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Arrangements
Except as set forth below, during the three months ended September 30, 2024, none of our officers or directors adopted, amended or terminated a “Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
On September 20, 2024, Douglas Kling, our Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement for the potential sale of up to 431,144 Ordinary Shares. The arrangement was initially adoptedon March 29, 2024.
On September 25, 2024, Louise Kooij, our Chief Accounting Officer terminated a Rule 10b5-1 trading arrangement for the potential sale of up to 213,073 Ordinary Shares. The arrangement was initially adopted on June 27, 2024.
On September 26, 2024, Douglas Kling, our Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement for the potential sale of up to 798,612 Ordinary Shares, subject to certain price thresholds and other conditions. The arrangement'sexpiration date is September 26, 2025.
On September 27, 2024, Ian Somaiya, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement for the potential sale of up to 200,000 Ordinary Shares, subject to certain price thresholds and other conditions. The arrangement'sexpiration date is September 30, 2025.
On September 27, 2024, Louise, Kooij, our Chief Accounting Officer, adopted a Rule 10b5-1 trading arrangement for the potential sale of up to 110,000 Ordinary Shares, subject to certain price thresholds and other conditions. The arrangement'sexpiration date is September 30, 2025.
There were no “non-Rule 10b5-1 trading arrangements,” as defined in Item 408(c) of Regulation S-K, entered into orterminated during thethree months ended September 30, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.